Long-Term Disease Stabilization in a Patient with Castration-Resistant Metastatic Prostate Cancer by the Addition of Lenalidomide to Low-Dose Dexamethasone and Celecoxib

摘要

Background: Treatment of castration-resistant prostate cancer (CRPC) remains a challenge considering that most patients are elderly men with significant comorbid-ities. Alternative treatment strategies to cytotoxic therapy should be explored. There is evidence that the continuous administration of cyclooxygenase 2 (COX-2) inhibitors and the immunomodulatory agents thalidomide or lenalidomide can result in long-term disease stabilization. Case Report: A 70-year-old patient with castration-resistant metastatic prostate cancer was treated with a combination of low-dose dexamethasone, celecoxib and subsequently lenalidomide. The patient had long-term disease stabilization for 33 months and a very good performance status despite moderate side effects, i.e. moderate Cushing's syndrome and mild laboratory hemato-logic toxicity. Conclusion: The addition of lenalidomide to low-dose dexamethasone and celecoxib resulted in an impressive long-term disease stabilization of CRPC in this patient, allowing him to lead an active life with a good quality of life.